A Pennsylvania-based healthcare company is seeing a pretty strong rally during Tuesday’s premarket after it was announced that %RothCapital analyst Jonathon Aschoff initiated coverage on the company with a buy rating with a price target of $5.00/share, which would be over +800% from yesterday’s close of $0.55.
Helius Medical Technologies Inc is a neurotech company focused on %NeurologicalWellness . The company's purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's first product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise. The company derives its revenue from Product Sales, fees and; license sources.
As previously mentioned, traders appear to be eager to get their hands on shares of %HeliusMedicalTechnologies () as shares are currently bid up at $0.6499/share (+18.16% implied open for sellers) at the time of writing.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.